ALLEVIATE-HFrEF Study

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

August 10, 2021

Primary Completion Date

March 10, 2022

Study Completion Date

June 1, 2022

Conditions
Heart Failure
Interventions
DEVICE

ALV1 System

The ALV1 system is designed to create a controlled size interatrial shunt via a proprietary intra-cardiac catheter. There is no temporary or permanent implant used to create or maintain the interatrial shunt. The therapy is intended to be delivered in a single procedure administered under general anesthesia in a cardiac catheterization laboratory.

Trial Locations (1)

Unknown

Tbilisi Heart & Vascular, Tbilisi

Sponsors
All Listed Sponsors
lead

Alleviant Medical, Inc.

INDUSTRY

NCT05133089 - ALLEVIATE-HFrEF Study | Biotech Hunter | Biotech Hunter